Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753804 · ClinicalTrials.gov registry record
A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Terminated
- Registry status
- 269
- Enrollment target
NCT01753804: Clinical Trial study, sponsored by BioMarin Pharmaceutical.
NCT01753804 is a clinical trial that was terminated before completion, run by BioMarin Pharmaceutical. The registered enrollment target is 269 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01753804 was terminated before completion, sponsored by BioMarin Pharmaceutical.
- TERMINATED
- Registry status
- 269 participants
- Enrollment target
Study Summary
To characterize the natural history and progression of Duchenne Muscular Dystrophy (DMD) to help inform the design of future studies, to capture biomarkers of safety and disease progression and to provide comparative data for the development of rare exons for which formal controlled trials are not feasible.
Primary Outcome
Participants are asked to walk at their own preferred speed on a fixed distance for 6 minutes. Subjects are warned of the time and that they may stop earlier if they feel unable to continue. Total distance walked within 6 minutes (or until stopping) is recorded.
Interventions
- OTHER Observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2012-09-01 |
| Est. Completion | 2016-10-01 |
Why NCT01753804 stopped before completion
NCT01753804 is an observational study that tracks outcomes without assigning an intervention. The registered 269 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Observational study is the first listed.
NCT01753804 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01753804 about?
NCT01753804 is a clinical study titled "A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.". To characterize the natural history and progression of Duchenne Muscular Dystrophy (DMD) to help inform the design of future studies, to capture biomarkers of safety and disease progression and to provide comparative data for the development of rare exons for which formal controlled trials are not f...
What is the current status of trial NCT01753804?
This trial is currently terminated. The enrollment target is 269 participants. The study started on 2012-09-01. Estimated completion is 2016-10-01.
What interventions are being tested in trial NCT01753804?
The interventions under investigation include: Observational study (OTHER).
Who is sponsoring clinical trial NCT01753804?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04802291 · 269 participants · NA
HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity
- NCT06500455 · 269 participants · Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
- NCT06630676 · 269 participants · NA
The Ability of Chronic Pain Patients to Self-diagnose Their Chief Source of Low Back Pain
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI